Back |
home / stock / xbio / xbio message board
Subject | By | Source | When |
---|---|---|---|
Rockafella: I have not got a chrystal ball but would like to think that we are talking a few months | Rockafella | investorshangout | 08/11/2015 1:21:32 PM |
mathsprof: The only question is - when will XBIO be properly trade-able on a main exchange. OTCQB ha | mathsprof | investorshangout | 08/11/2015 1:17:03 PM |
Rockafella: with such potential progressing through the clinical pipeline - orphan designated multi | Rockafella | investorshangout | 08/11/2015 1:02:08 PM |
Rockafella: Hi fellow investors - interest sarting to build on here - quite rightly so - my first po | Rockafella | investorshangout | 08/11/2015 12:57:12 PM |
ElmerS: Winston - I've been invested here for a number of years. As you know, they're yet to have a | ElmerS | investorshangout | 08/11/2015 11:41:30 AM |
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the qu...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...